Showing 781 - 800 results of 52,602 for search '(( 50 ((a decrease) OR (mean decrease)) ) OR ( a ((non decrease) OR (nn decrease)) ))', query time: 1.02s Refine Results
  1. 781
  2. 782
  3. 783
  4. 784
  5. 785
  6. 786
  7. 787

    Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: A Double-Blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy by Yong-Chul Kim (1637572)

    Published 2013
    “…</p><p>Results</p><p>The mean value of pcUACR at 12-week and 16-week visits (primary outcome) was decreased more in the Tac group compared to the control group (–52.0±26.4 vs –17.3±29.3%, p = 0.001). …”
  8. 788
  9. 789
  10. 790

    Decrease in comet tail moment (TM) with increasing concentration of () melphalan and () SJG-136 in AA8 cells by Peter H. Clingen (9612)

    Published 2011
    “…For each drug concentration, the TM of 50 cells was measured and the mean values calculated. …”
  11. 791
  12. 792
  13. 793
  14. 794

    ApoER2 expression increases Aβ production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulat... by Rodrigo A Fuentealba (77901)

    Published 2011
    “…<p><b>Copyright information:</b></p><p>Taken from "ApoER2 expression increases Aβ production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of γ-secretase activity"</p><p>http://www.molecularneurodegeneration.com/content/2/1/14</p><p>Molecular Neurodegeneration 2007;2():14-14.…”
  15. 795
  16. 796

    Data_Sheet_1_rdHSV-CA8 non-opioid analgesic gene therapy decreases somatosensory neuronal excitability by activating Kv7 voltage-gated potassium channels.docx by Munal B. Kandel (18526539)

    Published 2024
    “…These data demonstrate for the first time that vHCA8 produces Kv7 channel activation, which decreases neuronal excitability in nociceptors. This suppression of excitability may translate in vivo as non-opioid dependent behavioral- or clinical analgesia, if proven behaviorally and clinically.…”
  17. 797
  18. 798
  19. 799
  20. 800